Opportunity Information: Apply for RFA AI 15 024
Apply for RFA AI 15 024
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Partnerships for the Development of Host Targeted Therapeutics to Limit Antimicrobial Resistance (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.855 Allergy and Infectious Diseases Research 93.856 Microbiology and Infectious Diseases Research.
- This funding opportunity was created on Jun 5, 2015 and posted on Jun 5, 2015.
- Applicants must submit their applications by Sep 17, 2015. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $11,500,000.00 to eligible and selected applicants.
- Eligible applicants include: City or township governments State governments Public housing authorities/Indian housing authorities Small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Special district governments Independent school districts Public and State controlled institutions of higher education Native American tribal governments (Federally recognized) For profit organizations other than small businesses Private institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education County governments Native American tribal organizations (other than Federally recognized tribal governments).
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
Partnerships for the Development of Host Targeted Therapeutics to Limit Antimicrobial Resistance (R01) (Funding Opportunity Number RFA-AI-15-024) is an NIH discretionary grant opportunity designed to push new anti-infective strategies toward practical, preclinical readiness by focusing on the human host rather than directly attacking the bacteria. The central idea is to support milestone-driven research projects that develop candidate therapeutics aimed at host-encoded functions that bacteria rely on to establish infection or cause disease. Instead of targeting bacterial proteins that can mutate and develop resistance, these projects are meant to interfere with host pathways or factors required for bacterial infection, replication, virulence, proliferation, and/or pathogenesis, particularly for bacterial pathogens where antimicrobial resistance has become a serious public health concern.
The FOA emphasizes preclinical development and a partnership-style approach. That typically means applicants are expected to propose projects with clear, measurable go/no-go milestones, showing how a candidate host-targeted therapeutic will be advanced along a development path rather than staying at a purely exploratory stage. While the brief synopsis does not list specific pathogens in the excerpt provided, it makes clear the focus is on selected bacterial threats with significant resistance problems, implying that the work should be strongly justified by an antimicrobial resistance (AMR) rationale and demonstrate how a host-directed approach could reduce the likelihood of resistance or preserve the utility of existing antibiotics.
From a funding and administrative standpoint, this opportunity uses the NIH R01 mechanism (a standard research project grant) and falls under the health-related funding activity category. It is associated with CFDA numbers 93.855 (Allergy and Infectious Diseases Research) and 93.856 (Microbiology and Infectious Diseases Research). The estimated total funding amount listed is $11,500,000, and there is no cost sharing or matching requirement, meaning applicants are not required to contribute non-federal funds as a condition of the award.
Eligibility is broad and includes many types of domestic and non-domestic organizations. Eligible applicants include federal, state, county, city/township, and special district governments; public housing authorities; independent school districts; public and private institutions of higher education; nonprofits with or without 501(c)(3) status (with the noted exception categories); and for-profit organizations, including small businesses. The FOA also allows participation by tribal governments and tribal organizations, as well as a wide range of mission-focused institutions such as HBCUs, Hispanic-serving institutions, AANAPISIs, tribal colleges and universities, Alaska Native and Native Hawaiian-serving institutions, and faith-based or community-based organizations. Foreign organizations and regional organizations are also listed as eligible, along with U.S. territories or possessions. In practical terms, this breadth suggests NIH intended to attract both academic and translational development teams, including groups with drug development, pharmacology, or advanced preclinical capabilities.
Key dates show this was a time-limited announcement posted on June 5, 2015, created the same day, with an original and current closing date of September 17, 2015, and an archive date of October 18, 2015. That means the specific FOA is no longer open, but the summary remains useful as a reference point for similar NIH initiatives focused on host-directed therapeutics and AMR.
The administering agency is the National Institutes of Health, and the full announcement was made available through the NIH grants guide at the listed link: http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-15-024.html. For technical issues accessing the announcement, the contact provided is the NIH Office of Extramural Research (OER) webmaster (FBOWebmaster@OD.NIH.GOV), indicating the posted contact is primarily for announcement access or linking problems rather than scientific or grants management questions.
Overall, the opportunity is best understood as a targeted NIH effort to build a pipeline of host-targeted, preclinically validated therapeutic candidates against high-concern resistant bacterial pathogens, using milestone-based project management to keep development-oriented research on a clear, decision-driven track.
Frequently Asked Questions (FAQs)
What is the name of this funding opportunity?
The opportunity is titled Partnerships for the Development of Host Targeted Therapeutics to Limit Antimicrobial Resistance (R01).
What is the Funding Opportunity Number (FOA number)?
The Funding Opportunity Number is RFA-AI-15-024.
Which agency is administering this grant opportunity?
The administering agency is the National Institutes of Health (NIH).
What type of grant mechanism does this opportunity use?
This opportunity uses the NIH R01 mechanism (a standard research project grant).
What is the main scientific goal of this FOA?
The goal is to push new anti-infective strategies toward practical, preclinical readiness by developing host-targeted therapeutics that can limit or help address antimicrobial resistance (AMR).
What does "host-targeted therapeutics" mean in this FOA?
In this FOA, host-targeted therapeutics are candidate interventions aimed at host-encoded functions that bacteria rely on to establish infection or cause disease, rather than directly targeting bacterial proteins.
How is this approach different from traditional antibiotics?
Traditional approaches often target bacterial proteins, which can mutate and lead to resistance. This FOA emphasizes interfering with host pathways or factors required for bacterial infection, replication, virulence, proliferation, and/or pathogenesis, with the intent of reducing the likelihood of resistance or preserving the utility of existing antibiotics.
What types of pathogens are the focus?
The excerpt provided does not list specific pathogens. It indicates a focus on selected bacterial threats where antimicrobial resistance has become a serious public health concern, and projects are expected to be strongly justified by an AMR rationale.
What kinds of research activities are emphasized?
The FOA emphasizes preclinical development and advancing a candidate host-targeted therapeutic along a development path, rather than remaining at a purely exploratory stage.
What does "partnership-style approach" mean in this context?
Based on the synopsis provided, it means projects are expected to be milestone-driven with clear, measurable go/no-go milestones, consistent with development-oriented project management.
Are milestones and go/no-go decision points expected?
Yes. The synopsis states that applicants are expected to propose projects with clear, measurable go/no-go milestones that show how the candidate therapeutic will be advanced toward preclinical readiness.
Is this opportunity currently open for applications?
No. The FOA was time-limited. The closing date was September 17, 2015, and the archive date was October 18, 2015, so it is no longer open.
When was the opportunity posted?
The opportunity was posted on June 5, 2015 (and created the same day).
What is the estimated total funding amount listed?
The estimated total funding amount listed is $11,500,000.
Is cost sharing or matching required?
No. The synopsis states there is no cost sharing or matching requirement.
What is the funding activity category?
The opportunity is categorized under health-related funding activities.
Which CFDA numbers are associated with this FOA?
The associated CFDA numbers are 93.855 (Allergy and Infectious Diseases Research) and 93.856 (Microbiology and Infectious Diseases Research).
Who is eligible to apply?
Eligibility is broad and includes many domestic and non-domestic organization types, including governments, higher education institutions, nonprofits, and for-profit organizations (including small businesses), as well as tribal entities and a range of mission-focused institutions.
Are foreign organizations eligible?
Yes. The synopsis explicitly lists foreign organizations as eligible, along with regional organizations and U.S. territories or possessions.
Are for-profit organizations eligible?
Yes. The synopsis states that for-profit organizations, including small businesses, are eligible applicants.
Are institutions of higher education eligible?
Yes. Both public and private institutions of higher education are listed as eligible.
Are nonprofits eligible even if they do not have 501(c)(3) status?
Yes. The synopsis includes nonprofits with or without 501(c)(3) status (with noted exception categories referenced in the source summary).
Are tribal governments and tribal organizations eligible?
Yes. The synopsis includes tribal governments and tribal organizations as eligible.
Does the FOA encourage participation by specific institution types (e.g., HBCUs or Hispanic-serving institutions)?
Yes. The synopsis lists a wide range of institution types as eligible, including HBCUs, Hispanic-serving institutions, AANAPISIs, tribal colleges and universities, and other Alaska Native, Native Hawaiian-serving, faith-based, and community-based organizations.
Where can the full announcement be found?
The full announcement is available through the NIH Grants Guide at: http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-15-024.html.
Who should be contacted for technical issues accessing the announcement link?
For technical issues accessing the announcement, the contact provided is the NIH Office of Extramural Research (OER) webmaster at FBOWebmaster@OD.NIH.GOV.
Is the listed contact intended for scientific or grants management questions?
The synopsis indicates the listed contact is primarily for technical issues related to accessing the announcement (access/linking problems), rather than scientific or grants management questions.
What is the overall intent of the program, in practical terms?
In practical terms, it is a targeted NIH effort to help build a pipeline of preclinically validated, host-targeted therapeutic candidates against high-concern resistant bacterial pathogens, using a milestone-based approach to keep development on a decision-driven track.
Browse more opportunities from the same category: Health
Next opportunity: Adherence Studies in Adolescents with Chronic Kidney or Urologic Diseases (R01)
Previous opportunity: Musconetcong River Comprehensive Management Plan Implementation
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA AI 15 024
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA AI 15 024) also looked into and applied for these:
| Funding Opportunity |
|---|
| Prematurity Related Ventilatory Control (Pre Vent) Role in Respiratory Outcomes Clinical Research Centers (CRC) (U01) Apply for RFA HL 16 015 Funding Number: RFA HL 16 015 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Prematurity Related Ventilatory Control (Pre Vent) Role in Respiratory Outcomes Leadership and Data Coordinating Center (LDCC) (U01) Apply for RFA HL 16 016 Funding Number: RFA HL 16 016 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Exploiting RNA as a Target for HIV Interventions (R21) Apply for PA 15 272 Funding Number: PA 15 272 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Understanding HIV Persistence in Infants (R01) Apply for PA 15 271 Funding Number: PA 15 271 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Increasing Awareness and Implementation of the Standards for Adult Immunization Practice Through Apply for CDC RFA IP15 1502PPHF15 Funding Number: CDC RFA IP15 1502PPHF15 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,250,000 |
| Educating State level Stakeholders on Strategies to Address Winnable Battles in Public Health Apply for CDC RFA SO15 1501 Funding Number: CDC RFA SO15 1501 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,000,000 |
| Improving Immunization Collaboration Among Pharmacists and Other Healthcare Providers Financed Apply for CDC RFA IP15 1504PPHF15 Funding Number: CDC RFA IP15 1504PPHF15 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $800,000 |
| Open Design Tools for Speech Signal Processing (R01) Apply for RFA DC 16 001 Funding Number: RFA DC 16 001 Agency: National Institutes of Health Category: Health Funding Amount: $325,000 |
| Open Design Tools for Speech Signal Processing (R43/R44) Apply for RFA DC 16 002 Funding Number: RFA DC 16 002 Agency: National Institutes of Health Category: Health Funding Amount: $1,000,000 |
| PPHF 2015 Immunization Strengthening Surveillance for Diseases Among Newly Arrived Immigrants and Refugees financed solely by 2015 Prevention and Public Health Funds Apply for CDC RFA CK12 1205PPHFSUPP15 Funding Number: CDC RFA CK12 1205PPHFSUPP15 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $140,000 |
| Short Courses in High Priority Domains of Behavioral and Social Research on Aging (R25) Apply for RFA AG 16 010 Funding Number: RFA AG 16 010 Agency: National Institutes of Health Category: Health Funding Amount: $125,000 |
| Partnerships for the Development of Novel Assays to Predict Vaccine Efficacy (R01) Apply for RFA AI 15 033 Funding Number: RFA AI 15 033 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Grants to Support the Historically Black Colleges and Universities Health Services Research Grant Program Apply for CMS 1I0 15 001 Funding Number: CMS 1I0 15 001 Agency: Centers for Medicare Medicaid Services Category: Health Funding Amount: $215,000 |
| Grants to Support the Hispanic Health Services Research Grant Program Apply for CMS 1H0 15 001 Funding Number: CMS 1H0 15 001 Agency: Centers for Medicare Medicaid Services Category: Health Funding Amount: $215,000 |
| Health Workforce Research Center (HWRC) Program Apply for HRSA 15 148 Funding Number: HRSA 15 148 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Dental Preventive and Clinical Support Centers Program Apply for HHS 2015 IHS TDCP 0001 Funding Number: HHS 2015 IHS TDCP 0001 Agency: Indian Health Service Category: Health Funding Amount: $250,000 |
| National HIV Surveillance System (NHSS) Apply for CDC RFA PS13 130204CONT16 Funding Number: CDC RFA PS13 130204CONT16 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Novel or Enhanced Dental Restorative Materials for Class V Lesions (R01) Apply for RFA DE 16 007 Funding Number: RFA DE 16 007 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Guinea Health Service Delivery Apply for RFA OAA 15 000024 Funding Number: RFA OAA 15 000024 Agency: Guinea USAID Conakry Category: Health Funding Amount: $24,000,000 |
| PPHF 2015 Hospitals Promoting Breastfeeding Building Capacity of the Public Health System to Improve Population Health through National, Nonprofit Organizations Office for State, Tribal, Local and Territorial Support (OSTLTs) financed in part by 2 Apply for CDC RFA OT13 130203PPHF15 Funding Number: CDC RFA OT13 130203PPHF15 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA AI 15 024", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.